Why switching treatments isn’t always straightforward
In Spain, thousands of menopausal women have been left without access to Lenzetto, a hormone replacement therapy spray, due to ongoing supply disruptions. The shortage, which began in early 2026, has intensified across multiple regions, prompting concern among healthcare providers and patient advocacy groups. The European Commission has urged member states to inform doctors about alternative treatment options to mitigate the impact on women’s health.
Latest news
Leader of Jewish Greens Calls for Polanski to Step Down After Defeat
EU Unveils Critical Mineral Projects List Focused on Clean Energy Metals
Navanethem „Navi” Pillay Wins 2026 Nobel Peace Prize for Advancing Global Justice
The Supreme Court’s recent ruling has reignited the fight against conversion therapy for LGBTQ+ youthThe disruption stems from manufacturing delays at the primary production facility, which supplies Lenzetto to several European countries. Spanish health authorities confirmed that alternative gels and patches are available but noted that not all patients can switch easily due to individual health profiles or insurance coverage limitations. Pharmacists in Madrid and Barcelona reported increased inquiries from women experiencing sudden symptom recurrence, including hot flashes and sleep disturbances, after being unable to refill prescriptions.
What are the risks of untreated menopause symptoms?
Medical experts emphasize that hormone replacement therapy is highly individualized, and abrupt changes can lead to adverse effects or reduced efficacy. Dr. Elena Ruiz, an endocrinologist at Hospital Clínic in Barcelona, explained that some patients require precise dosing that alternatives may not provide. „We’re seeing women who stabilized on Lenzetto now struggling with fluctuating symptoms,” she said. The Spanish Agency for Medicines and Health Products has been working to secure emergency imports, but timelines remain uncertain.
Untreated menopausal symptoms can significantly affect quality of life and long-term health, increasing risks for osteoporosis, cardiovascular issues, and mental health challenges. Patient groups have called for faster regulatory responses and greater transparency from manufacturers. While no official figures on the number of affected women have been released, estimates suggest tens of thousands may be impacted nationwide.
What is Lenzetto used for? Lenzetto is a transdermal spray containing estradiol, prescribed to alleviate menopausal symptoms such as hot flashes, night sweats, and vaginal dryness by supplementing declining estrogen levels.
Frequently Asked Questions
Are there approved alternatives to Lenzetto in Spain? Yes, other forms of estrogen therapy, including gels, patches, and oral tablets, are authorized in Spain, but suitability depends on individual medical history and must be determined by a healthcare provider.
How long is the shortage expected to last? Authorities have not provided a definitive timeline, but they are coordinating with suppliers and exploring temporary import solutions to restore supply as soon as possible.